Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans.
Immutep and Monash announce first publication detailing how human LAG-3 Binds to MHC Class II
December 16, 2024 Australian Biotech
Latest Video
New Stories
-
New Zealand moves again to make it easier to access medicines
July 11, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 July
July 10, 2025 - - Podcast -
'The debate is frustrating but it is an opportunity to amplify acknowledged concerns'
July 10, 2025 - - Latest News -
Medibank to subsidise pharmacogenetic testing for members
July 10, 2025 - - Latest News -
Is this the missing link in pharma engagement strategies?
July 9, 2025 - - Latest News -
Stakeholders welcome medicinal cannabis crackdown
July 9, 2025 - - Latest News -
Might Australia be just a little hypocritical on pharmaceutical tariffs?
July 9, 2025 - - Latest News